Development of antibody therapeutics, from early stage research to preclinical and clinical development, requires ever-increasing amounts of reagents. To meet the challenge of furnishing a diverse and full pipeline, we utilise several different transient platforms. Through continuous optimisation, streamlining and automation of component parts of our panel of platforms (utilising both HEK293 and CHO host cells with a variety of transfection methods), we now have the capability to produce microgram-to-gram quantities of panels of purified antibodies and antibody fragments in as few as four weeks from receipt of plasmid DNA.
Biotechnology
Cell Biology
Cancer Research
Molecular Biology
Genomics
Biomarkers
Gene Expression
Crispr-Cas9
Bioinformatics
Pcr/rt-Pcr/real-Time Pcr
Biomedical Engineering
Immunology
Cancer Diagnostics
Drug Discovery
Cell Culture
North America57%
Asia17%
South America13%
Europe9%
Africa4%
Website Visitors100%
Research Scientist21%
Student21%
Scientist16%
Medical Doctor/Specialist11%
Executive11%
Educator/Faculty5%
Facility/Department Manager5%
Medical Laboratory Technician5%
Post Doc5%
Academic Institution17%
Biotech Company13%
Life Science Company9%
Clinical Laboratory4%
Research Institute4%
Media4%
Manufacturer - Other4%
Government4%
Other4%